Compare CHW & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHW | FULC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.0M | 535.5M |
| IPO Year | 2007 | 2019 |
| Metric | CHW | FULC |
|---|---|---|
| Price | $8.25 | $7.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 232.2K | ★ 916.8K |
| Earning Date | 01-01-0001 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.30 | $3.55 |
| 52 Week High | $8.34 | $15.74 |
| Indicator | CHW | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 67.10 | 44.20 |
| Support Level | $7.90 | $7.40 |
| Resistance Level | $8.27 | $8.24 |
| Average True Range (ATR) | 0.14 | 0.48 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 91.80 | 30.51 |
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.